SELLAS Life Sciences Group, Inc. SLS
14.86 USD -3.09 (-17.21%)
Regular-session close
15.00 +0.14 +0.94%
After hours · Nov 19, 7:59 PM ET
14.23 Day range 16.54
1.39 52-week range 24.89
- YTD
- +294.16%
- 1 year
- +877.63%
News
benzinga.com Dow Tumbles 900 Points; Walmart Raises Full-Year Guidance U.S. stocks fell sharply, with the Dow down over 900 points. Walmart beat Q3 expectations and raised its full-year outlook.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers VivoSim Labs (NASDAQ:VIVS) shares increased by 82.0% to $0.22 during Thursday's regular session. The market value of their outstanding shares is at $2.4 million. Marker Therapeutics…
benzinga.com Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise as Wall Street Awaits Anthropic’s Listing— PANW, NTES, SLS in Focus (UPDATED) U.S. stock futures rose on Thursday, as the Dow Jones, S&P 500, and Nasdaq 100 indices advanced, following Wednesday's mixed close.
benzinga.com NetEase Downbeat Q3 Results, Joins Red Robin, Sellas Life Sciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures rose, but NetEase slid 5.2% after missing Q3 earnings and sales estimates; Red Robin and Sellas also fell sharply premarket.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) stock increased by 62.9% to $0.44 during Thursday's pre-market session. Pulmatrix (NASDAQ:PULM) stock rose 13.58% to $1.52. The company's market cap stands at $4.8…
benzinga.com Why Palo Alto Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket Palo Alto Networks surged 9.1% after beating Q1 estimates and issuing strong Q2 guidance; several stocks rose while others fell premarket.
globenewswire.com SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of…
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed Ahead of FOMC Minutes— NVDA, AAOI, PANW in Focus (UPDATED) U.S. stocks rose on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures advanced, following Tuesday's lower close.
benzinga.com Dolby Laboratories, Jumia Technologies, Applied Optoelectronics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session Dolby slid on below-estimate FY27 guidance, while Red Cat, Jumia, BGIN and other stocks declined in premarket trading.
benzinga.com Why Pony AI Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket Pony AI rose 10.6% after beating Q3 loss estimates but missing sales; Autozi led gainers, while IRIDEX fell 17.6% on results and guidance.
globenewswire.com SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia global en pacientes con leucemia mieloide aguda - El ensayo REGAL alcanzó su criterio principal de valoración: GPS demostró una reducción estadísticamente significativa y clínicamente relevante del 41 % en el riesgo de muerte, con una mediana de…
globenewswire.com SELLAS Life Sciences Divulga Dados Positivos do Estudo REGAL Pivotal de Fase 3, Indicando que Galinpepimut-S (GPS), a Vacina Imunoterapêutica Contra o Câncer, Demonstrou uma Melhora Estatisticamente Significativa e Clinicamente Relevante na Sobrevida Global de Pacientes com Leucemia Mieloide Aguda - O estudo REGAL atingiu seu desfecho primário, com o GPS demonstrando uma redução estatisticamente significativa e clinicamente relevante no risco de morte de 41%, com uma sobrevida global mediana…
seekingalpha.com SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks Transcript SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia November 17, 2026 7:45 AM EST Company Participants Angelos…
globenewswire.com SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release,…
benzinga.com S&P 500 Down 1%; Disney Posts Upbeat Earnings U.S. stocks fell over 1%; Disney beat estimates, while SLS and GP surged. Oil, gold and silver rose as global markets mostly declined.
benzinga.com Amer Sports, Sellas Life Sciences, Similarweb And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell, but Amer Sports surged on strong results and raised guidance; Sellas jumped 165%, while several other stocks posted gains.
benzinga.com Dow Falls Over 200 Points; US Retail Sales Rise 0.2% In October U.S. stocks were mixed as the Dow fell 200+ points; retail sales rose 0.2%, oil gained 1.5%, and SLS surged 177%.
benzinga.com SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial, SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to…
benzinga.com SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial, SELLAS Life Sciences reports positive Phase 3 REGAL results as galinpepimut-S cuts death risk by 41% in acute myeloid leukemia patients.benzinga.com SELLAS Life Sciences Announces Topline Results From Its Phase 3 REGAL Trial Evaluating Galinpepimut-S In Patients With Acute Myeloid Leukemia Met Primary Endpoint REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus…
globenewswire.com SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia - REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus…
schaeffersresearch.com Sellas Life Sciences Stock Jumps on Trial Results Timeline Sellas Life Sciences Group Inc (NASDAQ:SLS) stock is up 7% to trade at $8.59 after the biotech company announced that results from its closely watched leukemia trial are expected later this month.benzinga.com SELLAS Life Sciences Gr Q3 EPS $(0.05), Inline SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3…
globenewswire.com SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial…benzinga.com SELLAS Life Sciences To Present Data From Completed Phase 2 Study Of SLS009 For Treatment Of R/R AML, At 68th ASH Annual Meeting And Exposition − Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients…
globenewswire.com SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026 − Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com SELLAS Life Sciences Stock Stumbles: What's Going On? SELLAS Life Sciences Group shares are falling Wednesday as the company's Phase 3 leukemia study moves toward its final analysis.benzinga.com SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer
globenewswire.com SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia - Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -
defenseworld.net SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What Happened SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report)'s stock price fell 11.2% during mid-day trading on Friday. The stock traded as low as $9.75 and last traded at $10.0740. Approximately…
gurufocus.com SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier StudyPR NewswireSTOCKHOLM, Oct. 15, 2026STOCKHOLM, Oct. 15, 2026 /PRNewswire/ -- SciBa
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
globenewswire.com SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
